Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335710 | 1.00 | FUCA1 (0.58) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL15477204 | 1.00 | FUCA1 (0.58) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL5793338 | 1.00 | FUCA1 (0.58) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| Hydrochloric Acid SCHEMBL14780325 | 0.98 | FUCA1 (0.56) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| Hydrochloric Acid SCHEMBL14780326 | 0.98 | FUCA1 (0.56) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL9180991 | 0.89 | ALDH1A1 (0.53) | GBA1SIGMAR1DRD2DRD3ALDH1A1 | |
| SCHEMBL25024428 | 0.86 | FUCA1 (0.54) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL30233713 | 0.86 | FUCA1 (0.54) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL16775256 | 0.84 | FUCA1 (0.64) | FUCA1GBA1SIGMAR1S1PR1S1PR5 | |
| SCHEMBL16759827 | 0.84 | FUCA1 (0.64) | FUCA1GBA1SIGMAR1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| US-9856262-B2 | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| WO-2005026121-A1 | PROCESS FOR THE PREPARATION OF (1α, 5α, 6α)-6-AMINOMETHYL-3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004089364-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089900-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
| EP-0413455-B1 | Azabicyclo quinolone carboxylic acids | PFIZER (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5391763-A | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5229396-A | Anti-bacterial azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991002526-A1 | AZABICYCLO QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| EP-0413455-A2 | Azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | FUCA1 2760/4885GBA1 209/4885SIGMAR1 3467/4885 |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | FUCA1 3598/4885GBA1 2554/4885SIGMAR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.